License deal with A*STAR to develop cancer antibodies
License deal with A*STAR to develop cancer antibodies
Search
EMA filing acceptance and validation for spesolimab
The European Medicines Agency has accepted and validated the marketing authorization application for spesolimab in generalized pustular psoriasis
Generalized pustular psoriasis at EADV 2021
Dr. Emmanuelle Clerisme-Beaty (former Associate Head of Medicine - Inflammation, Boehringer Ingelheim) reflects on developments for GPP at the EADV congress, 2021
Groundbreaking oncology research zongertinib
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
Jens Barthelmes
My career challenge at Boehringer Ingelheim by Jens Barthelmes. Read it now!
InPedILD_trial_enrollment
First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
biolabs-heidelberg
Boehringer Ingelheim supports the launch of BioLabs first European Location in Heidelberg.
The Research Process
The Research Process
The METAmorphosis
At Boehringer Ingelheim’s META offices in the Middle East, Turkey and Africa all offices in the region are already free of single-use plastic.
Big Little Things in cancer: small things, big impacts
Little things can be a big deal when you are living with or treating cancer. Sometimes the small things are the most powerful.
Open Innovation at Boehringer Ingelheim
Learn more about how we’re working across the innovation community to advance research and accelerate the development of new medicines
European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis
European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis
Breakthrough in Artificial Intelligence ChatGPT
Is ChatGPT the AI revolution we were waiting for or only media hype? Experts from Boehringer Ingelheim take a close look.
The Unwearable Collection™: Fashion Inspired by GPP
An introduction to The Unwearable Collection™: fashion inspired by the experiences of living with GPP, designed by Bart Hess
CARMELINA-elderly-analysis
CARMELINA® outcome trial subgroup analysis demonstrates long-term cardiovascular and renal safety data in older people with type 2 diabetes
Edda Dankmeyer
Edda Dankmeyer is our Lead of Sustainable Development Communications. She tells us where her passion for sustainability comes from, why she joined us, and how sustainable development can be a key differentiator for the company.
Celebrating Women in Technology
We want to elevate women in technology: empower them, affirm their potential and enable them to soar to new heights
Ranking in the top 25% in EcoVadis Sustainability Assessment
Boehringer Ingelheim has received a silver medal from EcoVadis in the 2023 sustainability assessment, including above industry average scores.
European Election: Europe needs our vote
This week, over 400 million citizens from the 27 European Union (EU) Member States will be able to elect a new European Parliament. Our vote can help to make a better and stronger Europe..
SPEVIGO CHMP positive opinion new indications
CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®
Breaking prejudice in lung cancer
At Boehringer Ingelheim, addressing patient needs and fighting stigma in lung cancer care are two focus topics of the patient engagement team in oncology.
Acquisition expands research in cancer immunology
Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
collaboration-proxygen-molecular-glue-degraders
Boehringer Ingelheim collaborates with Proxygen to explore molecular glue degraders – a novel approach to fight cancer.
CAROLINA-CARMELINA-Asia-analysis
CAROLINA® and CARMELINA® outcome trial subgroup analyses demonstrate cardiovascular and renal safety data in Asian adults with type 2 diabetes
Uncommon_Mutations_Database
New database of published clinical outcomes from patients with uncommon EGFR mutations in advanced NSCLC treated with afatinib is available for global clinician use